Match!
Morten Kvistholm Jensen
Aarhus University Hospital
CardiologyAlcohol septal ablationHypertrophic cardiomyopathyDiabetes mellitusMedicine
30Publications
9H-index
372Citations
What is this?
Publications 30
Newest
#1Morten Kvistholm Jensen (Aarhus University Hospital)H-Index: 9
#2Lothar Faber (RUB: Ruhr University Bochum)H-Index: 31
Last. Josef Veselka (Charles University in Prague)H-Index: 22
view all 16 authors...
2 CitationsSource
#1Josef Veselka (Charles University in Prague)H-Index: 22
#2Lothar Faber (RUB: Ruhr University Bochum)H-Index: 31
Last. Morten Kvistholm Jensen (Copenhagen University Hospital)H-Index: 9
view all 14 authors...
1 CitationsSource
#1Josef Veselka (Charles University in Prague)H-Index: 22
#2Lothar Faber (RUB: Ruhr University Bochum)H-Index: 31
Last. Morten Kvistholm Jensen (Copenhagen University Hospital)H-Index: 9
view all 15 authors...
Based on European guidelines, alcohol septal ablation (ASA) for hypertrophic obstructive cardiomyopathy (HOCM) is indicated only in patients with interventricular septum (IVS) thickness > 16 mm. The aim of this study was to evaluate the short- and long-term outcomes in ASA patients with mild
Source
#1Pyotr G. Platonov (Lund University)H-Index: 29
#2Kristina H. Haugaa (University of Oslo)H-Index: 31
Last. Jesper Hastrup Svendsen (UCPH: University of Copenhagen)H-Index: 45
view all 14 authors...
Implantable cardioverter-defibrillator (ICD) therapy remains a corner stone of sudden cardiac death (SCD) prevention in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC). We aimed to assess predictors of appropriate ICD therapies in the Scandinavian cohort of ARVC patients who received ICD for primary prevention of SCD. Study group comprised of 79 definite ARVC patients by 2010 Task Force criteria (60% male, age at ICD implant 39 ± 14 years) who were enrolled in the Nordic ARV...
Source
#1Max LiebregtsH-Index: 9
#2Lothar Faber (RUB: Ruhr University Bochum)H-Index: 31
Last. Josef Veselka (Charles University in Prague)H-Index: 22
view all 12 authors...
9 CitationsSource
#1Hedvig Andersson (UM: University of Michigan)H-Index: 7
#2Frants PedersenH-Index: 21
Last. Peter Clemmensen (University of Southern Denmark)H-Index: 39
view all 13 authors...
12 CitationsSource
#1Josef Veselka (Charles University in Prague)H-Index: 22
#2Lothar Faber (RUB: Ruhr University Bochum)H-Index: 31
Last. Max LiebregtsH-Index: 9
view all 16 authors...
Abstract Background The current American College of Cardiology Foundation/American Heart Association guidelines on hypertrophic cardiomyopathy state that institutional experience is a key determinant of successful outcomes and lower complication rates of alcohol septal ablation (ASA). The aim of this study was to evaluate the safety and efficacy of ASA according to institutional experience with the procedure. Methods We retrospectively evaluated 1310 patients with symptomatic obstructive hypertr...
10 CitationsSource
#1Kim Munk (Aarhus University Hospital)H-Index: 10
#2Morten Kvistholm Jensen (Aarhus University Hospital)H-Index: 9
Source
#1Max LiebregtsH-Index: 9
#2Lothar FaberH-Index: 31
Last. Josef VeselkaH-Index: 22
view all 13 authors...
Source
#1Josef Veselka (Charles University in Prague)H-Index: 22
#2Lothar Faber (RUB: Ruhr University Bochum)H-Index: 31
Last. Morten Kvistholm Jensen (Copenhagen University Hospital)H-Index: 9
view all 17 authors...
Background The long‐term efficacy and safety of alcohol septal ablation (ASA) in patients with highly symptomatic hypertrophic obstructive cardiomyopathy has been demonstrated. The aim of this study was to evaluate the long‐term outcomes of mildly symptomatic patients with hypertrophic obstructive cardiomyopathy treated with ASA. Methods and Results We retrospectively evaluated consecutive patients enrolled in the Euro‐ASA registry (1427 patients) and identified 161 patients (53±13 years; 27% wo...
9 CitationsSource
123